[Federal Register Volume 69, Number 24 (Thursday, February 5, 2004)]
[Notices]
[Page 5548]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-2396]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Prospective Grant of Exclusive License: Diagnostics of Fungal 
Infections

AGENCY: Technology Transfer Office, Centers for Disease Control and 
Prevention (CDC), Department of Health and Human Services.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is a notice in accordance with 35 U.S.C. 209(e) and 37 
CFR 404.7(a)(1)(i) that the Centers for Disease Control and Prevention 
(CDC), Technology Transfer Office, Department of Health and Human 
Services (DHHS), is contemplating the grant of a worldwide, limited 
field of use, exclusive license to practice the inventions embodied in 
the patent application referred to below to TNB Laboratories, Inc. 
(TNB) having a place of business in St. Johns, Newfoundland. The patent 
rights in these inventions have been assigned to the government of the 
United States of America. The patent application to be licensed is:
    Title: ``Latent Human Tuberculosis Model, Diagnostic Antigens, and 
Methods of Use,'' U.S. Patent Application Serial No.: 10/250,930 (TBC).
    Status: Pending.
    Issue Date: N/A.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.

Technology

    This technology adds a new level of specificity in the 
identification of Tuberculosis. It can be incorporated into a device to 
diagnose Latent Human Tuberculosis.

ADDRESSES: Requests for a copy of this patent application, inquiries, 
comments, and other materials relating to the contemplated license 
should be directed to Andrew Watkins, Director, Technology Transfer 
Office, Centers for Disease Control and Prevention (CDC), 4770 Buford 
Highway, Mailstop K-79, Atlanta, GA 30341, telephone: (770) 488-8610; 
facsimile: (770) 488-8615. Applications for a license filed in response 
to this notice will be treated as objections to the grant of the 
contemplated license. Only written comments and/or applications for a 
license which are received by CDC within sixty days of this notice will 
be considered. Comments and objections submitted in response to this 
notice will not be made available for public inspection, and, to the 
extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552. A signed Confidential Disclosure 
Agreement (available under Forms @ http://www.cdc.gov/tto) will be 
required to receive a copy of any pending patent application.

    Dated: January 29, 2004.
Joseph R. Carter,
Deputy Chief Operating Officer, Centers for Disease Control and 
Prevention.
[FR Doc. 04-2396 Filed 2-4-04; 8:45 am]
BILLING CODE 4163-18-P